Garadacimab (development code CSL-312 or Factor XIIa mAb) is an investigational, fully human monoclonal antibody being developed for the preventive treatment of hereditary angioedema (HAE) attacks. It represents a novel, targeted approach to HAE therapy. Garadacimab functions as a highly selective inhibitor of activated Factor XII (Factor XIIa). By binding with high affinity to Factor XIIa, it blocks its enzymatic activity. This inhibition prevents Factor XIIa from initiating the contact activation pathway (also known as the intrinsic pathway) of the coagulation cascade. Since this pathway is the primary driver of excessive bradykinin production in HAE, garadacimab aims to prevent the formation of bradykinin at its source, thereby reducing the frequency and severity of HAE attacks.